Literature DB >> 21832938

Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection.

Nicole L Yates1, Judith T Lucas, Tracy L Nolen, Nathan A Vandergrift, Kelly A Soderberg, Kelly E Seaton, Thomas N Denny, Barton F Haynes, Myron S Cohen, Georgia D Tomaras.   

Abstract

OBJECTIVE: Different HIV-1 antigen specificities appear in sequence after HIV-1 transmission and the immunoglobulin G (IgG) subclass responses to HIV antigens are distinct from each other. The initial predominant IgG subclass response to HIV-1 infection consists of IgG1 and IgG3 antibodies with a noted decline in some IgG3 antibodies during acute HIV-1 infection. Thus, we postulate that multiple antigen-specific IgG3 responses may serve as surrogates for the relative time since HIV-1 acquisition.
DESIGN: We determined the magnitude, peak, and half-life of HIV-1 antigen-specific IgG1 and IgG3 antibodies in 41 HIV-1-infected individuals followed longitudinally from acute infection during the first appearance of HIV-1-specific antibodies through approximately 6 months after infection.
METHODS: We used quantitative HIV-1-binding antibody multiplex assays and exponential decay models to estimate concentrations of IgG1 and IgG3 antibodies to eight different HIV-1 proteins including gp140 Env, gp120 Env, gp41 Env, p66 reverse transcriptase, p31 Integrase, Tat, Nef, and p55 Gag proteins during acute/recent HIV-1 infection.
RESULTS: Among HIV-1-specific IgG3 responses, anti-gp41 IgG3 antibodies were the first to appear. We found that anti-gp41 Env IgG3 and anti-p66 reverse transcriptase IgG3 antibodies, in addition to anti-Gag IgG3 antibodies, each consistently and measurably declined after acute infection, in contrast to the persistent antigen-specific IgG1 responses.
CONCLUSION: The detailed measurements of the decline in multiple HIV-specific IgG3 responses simultaneous with persistent IgG1 responses during acute and recent HIV-1 infection could serve as markers for detection of incident HIV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21832938      PMCID: PMC3667583          DOI: 10.1097/QAD.0b013e32834b348e

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  30 in total

1.  Rapid response of marginal zone B cells to viral particles.

Authors:  Dominique Gatto; Christiane Ruedl; Bernhard Odermatt; Martin F Bachmann
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

2.  Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG.

Authors:  J Klasse; J Blomberg
Journal:  J Infect Dis       Date:  1987-12       Impact factor: 5.226

3.  IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages.

Authors:  K Ljunggren; P A Broliden; L Morfeldt-Månson; M Jondal; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

4.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.

Authors:  P A Broliden; L Morfeldt-Månsson; J Rosen; M Jondal; B Wahren
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

6.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence.

Authors:  Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

7.  Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection.

Authors:  Kelly A Curtis; M Susan Kennedy; Man Charurat; Abdulsalami Nasidi; Kevin Delaney; Thomas J Spira; S Michele Owen
Journal:  AIDS Res Hum Retroviruses       Date:  2011-06-17       Impact factor: 2.205

8.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  Isotypic restriction of the antibody response to human immunodeficiency virus.

Authors:  J Khalife; B Guy; M Capron; M P Kieny; J C Ameisen; L Montagnier; J P Lecocq; A Capron
Journal:  AIDS Res Hum Retroviruses       Date:  1988-02       Impact factor: 2.205

10.  Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression.

Authors:  J S McDougal; M S Kennedy; J K Nicholson; T J Spira; H W Jaffe; J E Kaplan; D B Fishbein; P O'Malley; C H Aloisio; C M Black
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

View more
  47 in total

1.  Methods for comparing durability of immune responses between vaccine regimens in early-phase trials.

Authors:  Ted Westling; Michal Juraska; Kelly E Seaton; Georgia D Tomaras; Peter B Gilbert; Holly Janes
Journal:  Stat Methods Med Res       Date:  2019-01-09       Impact factor: 3.021

2.  Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Authors:  Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

3.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Authors:  James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts
Journal:  JCI Insight       Date:  2017-04-20

4.  High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.

Authors:  Eric R Weiss; Galit Alter; Javier Gordon Ogembo; Jennifer L Henderson; Barbara Tabak; Yasin Bakiş; Mohan Somasundaran; Manuel Garber; Liisa Selin; Katherine Luzuriaga
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

5.  Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut.

Authors:  Venkateswarlu Chamcha; Andrew Jones; Bernard R Quigley; June R Scott; Rama Rao Amara
Journal:  J Immunol       Date:  2015-10-19       Impact factor: 5.422

6.  Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients.

Authors:  Yulong Li; Min Yang; Rui Zhang; Wan Liu; Kuo Zhang; Wei Wen; Lang Yi; Qiaoxian Wang; Mingju Hao; Hui Yang; Jianmin Chang; Jinming Li
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

7.  Workshop summary: Novel biomarkers for HIV incidence assay development.

Authors:  Usha K Sharma; Marco Schito; Alex Welte; Christine Rousseau; Joseph Fitzgibbon; Brandon Keele; Stuart Shapiro; Andrew McMichael; David N Burns
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-24       Impact factor: 2.205

8.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples.

Authors:  Eric P Brown; Anna F Licht; Anne-Sophie Dugast; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Immunol Methods       Date:  2012-09-27       Impact factor: 2.303

Review 9.  B-cell responses to HIV infection.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 10.  Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Authors:  Margaret E Ackerman; Galit Alter
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.